Blog
Contributors
Products
Subscribe
Contact Us
  • Search the Blog
  • Search for Topics
  • Search for Keywords
  • Search for Authors
1 min read

We’ve Been Shortlisted in the 2021 SelectScience Scientists' Choice Awards®

BY Editorial Team |May 28 2021
Laboratory scientists across the globe are invited to vote for their favorite clinical products of 2020. Here’s how.
We’ve Been Shortlisted in the 2021 SelectScience Scientists' Choice Awards®

The 2021 Scientists Choice Awards®

SelectScience’s annual Scientists' Choice Awards is celebrating its 14th anniversary by honoring the most innovative and effective technologies of the past year. The awards provide scientists worldwide with the opportunity to acknowledge the instruments, assays, tools, or consumables that have made the most difference to their work.

Thanks to our loyal customers, we’re delighted to announce the Access SARS-CoV-2 IgM assay > has been nominated in the Best New Clinical Assay/Kit of 2020 category.

Our high-sensitivity and high-specificity SARS-CoV-2 IgM assay > has market-leading accuracy with a high positive predictive value (PPV) and a high negative predictive value (NPV). This provides clinicians with useful immune response information and may help determine if their patients have had a recent COVID-19 infection.

Casting Your Vote

Voting closes Sunday, June 13, 2021. All scientists who cast their vote for their favorite clinical products of 2020 will be entered into a drawing for a chance to win a $500/£400/450 € Amazon Gift Card from SelectScience.

Interested in sharing your thoughts?

Vote now
COVID-19 Innovation
Editorial Team
Editorial Team
The Beckman Coulter editorial team brings you timely news and resources focused on elevating clinical laboratory performance and advancing patient care.
See all by Editorial Team

Sickle Cell 101: Increasing Awareness and Understanding

Sickle Cell 101: Increasing Awareness and Understanding

BY Ahmed Bentahar, M.D., Ph.D. |June 19 2025
3 min read
In honor of World Sickle Cell Awareness Day, we recognize Sickle Cell Disease, a condition that disproportionately affects people of African descent 1,2
Read More
Advancing Your Clinical Capabilities

Advancing Your Clinical Capabilities

BY Matt Maxfield |May 23 2025
5 min read
Explore real-world examples of how our solutions are helping advance clinical capabilities every day, all around the world.
Read More
Syphilis Diagnostics: Then and Now

Syphilis Diagnostics: Then and Now

BY Tobin Efferen, MD, MS |April 30 2025
5 min read
Early detection through testing can help prevent the further transmission of syphilis and allow for timely treatment, reducing the risk of severe health complications of tertiary syphilis like organ damage and death.
Read More
Products
Support
Company Newsletter
Beckman Coulter Life Sciences
Stay Connected
Products
Support
Company
Newsletter
Beckman Coulter Life Sciences
Stay Connected


Information addressed to health professionals. The products presented on this site are for professional use only, and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

 

© 2025 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. 

All trademarks used herein are the property of their respective owners.

U.S. Government Users Restricted Rights - As per GSA ADP Schedule Contract with Beckman Coulter, Inc., the use, duplication or disclosure is restricted as follows: Beckman Coulter hereby authorizes user to copy those documents published on the World Wide Web by Beckman Coulter, for noncommercial use, and only within the user's organization. Except as expressly provided above, nothing contained herein shall be construed as granting any license or right under any Beckman Coulter copyright. Nothing contained herein shall be construed as granting by implication, estoppel or otherwise any license or right under any patent or trademark of Beckman Coulter or any third party.